Navigation Links
Stemedica Forms Cardiology Division. Sergey Sikora, PhD Appointed As Division President
Date:2/15/2013

San Diego, CA (PRWEB) February 15, 2013

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research, development, and clinical applications announced today that it has formed a Cardiology Division to advance the Company’s national and international clinical trials in chronic heart failure, acute myocardial infarct (AMI) and other cardiac conditions.

Stemedica has made considerable progress in the translational applications of its ischemia tolerant adult allogeneic stem cells for cardiovascular diseases. The Company recently gained FDA approval for a multi-center Phase II clinical trial for intravenous treatment of AMI with its Stemedyne™-MSC product. Regulatory approval has also been granted to the National Medical Research Center in Astana, Kazakhstan for a Phase III trial with Stemedyne™-MSC. A Phase II clinical trial for chronic heart failure has begun at Hospital Angeles in Mexico. Additional cardiology trials with Stemedyne™-MSC are being planned in several countries around the world, including Switzerland and Indonesia.    

Dr. Sergey Sikora, the newly appointed Cardiology Division President, brings 12 years of experience in biomedical research, diagnostics and therapeutics in cardiology. Prior to Stemedica, he served as Senior Vice President and Scientific Advisory Board member of the FirstMark Cardiology Diagnostics Division of GenWay Inc. Dr. Sikora also worked with the Burnham Institute where he developed a novel bioinformatics/experimental biology streamlining methods for rapid experimental conformation of computational predictions. His work analyzing the genome of severe acute respiratory syndrome (SARS) resulted in a U.S. patent and a number of published research articles. Dr. Sikora obtained his PhD in molecular biology from UCLA and MBA from the Rady School of Management at the University of California, San Diego.

Nikolai Tankovich, MD, PhD, President and Chief Medical Officer of Stemedica commented, “This is a pivotal time to have an executive of Dr. Sikora’s caliber join our team. We have extensive interest worldwide in the application of our unique stem cells for heart and blood vessel diseases. Dr. Sikora will be coordinating the efforts of clinicians and researchers at multiple sites around the world.”

Dr. Sikora commented, “I am excited to contribute to Stemedica’s growth by utilizing my experience and contacts in the cardiology field to advance the science and translational efforts of stem cell treatments.”

Maynard Howe, PhD, Vice Chairman and CEO of Stemedica noted, “Our strategy as a company is to expand our clinical trials using our multiple cell lines to address specific medical indications. The company will continue to acquire additional strategic partners that share our vision of bringing our products to the millions of people around the world who suffer from serious cardiac conditions.”

About Stemedica Cell Technologies, Inc. http://www.stemedica.com
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and acute myocardial infarction. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.

For more information regarding Stemedica Cell Technologies, Inc., contact Dave McGuigan at dmcguigan (at) stemedica.com.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10435703.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Stemedica and Scripps to Jointly Investigate Therapeutic Effect of Ischemia Tolerant Mesenchymal Stem Cells (itMSC) and Stem Cell Factors in Lung Injury and Sepsis
2. Marker distinguishes more-aggressive from less-aggressive forms of chronic leukemia
3. Metformin Outperforms Common Class of Diabetes Drugs in Study
4. Miami Children’s Hospital Performs First Nerve Repair Surgery Using Avance® Nerve Graft Technology
5. Study to evaluate zoning code reforms and physical activity
6. US performs worst on potentially preventable death rates compared to France, Germany, and the UK
7. Making People Sign Forms at the Top May Keep Them Honest
8. 4,000 analytics experts come to Phoenix for INFORMS Annual Meeting
9. Networks it takes a village approach improves dementia care and informs research, study shows
10. UCLA performs first breathing lung transplant in United States
11. FDA Clears Laser for all Critical Steps in Cataract Surgery: Center For Sight Performs the Most LENSAR Laser Procedures in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... While it’s ... poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , ... medication in darkness or restricted lighting. As such, it eliminates the need to turn ...
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology: